DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 276 participants.
Also called NCT04124484
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 276 participants
- Registry
-
NCT04124484
-
- Other papers using this trial's data
- Efficacy and safety of DBPR108 monotherapy in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled, phase II clinical trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT04124484. Randomized; quadruple masking; primary purpose treatment. Start 2017-10-17 (actual); primary completion 2019-02-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- DBPR108 Tablets in Type 2 Diabetes Mellitus Patients
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
- Intervention (Drug)
- DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
- Intervention (Drug)
- DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
- Intervention (Drug)
- Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct04124484- Content hash
4a92aa0716f7e965e112b47453d7b956574ddaff6a01428898b3f64c3740fb34